CYTH
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Cyngn's rating stands at Neutral, reinforced by a composite of 35.1 amidst a landscape of mixed pillar contributions. With the strongest support from the regulatory pillar, this component underscores the company's standing in a highly scrutinized jurisdiction with a relatively favorable posture. However, the overall conviction remains moderate at 3 out of 5, largely due to the constrained fundamentals driven by both disappointing revenue trends and a lack of operational efficiency. Market dynamics and editorial visibility offer lower comparative contributions, further solidifying the Neutral rating band.
The underlying weaknesses in Cyngn's financial data are pronounced. Year-over-year revenue growth has been negative, a stark contrast overshadowed by an otherwise strong gross margin exceeding industry norms. Yet, this is offset by significant negative operating margins, eroding potential profitability. The company’s financial condition is notably stretched, marked by a precarious cash burn ratio that indicates a delicate runway. The absence of net income further compounds concerns around financial sustainability, signaling a critical need for revenue stabilization or alternative financial strategies.
Going forward, stakeholders should focus on regulatory developments, as they hold the most promise for improved market positioning. With no recent enforcement hits, maintaining compliance status and navigating the complex regulatory landscape will be key to mitigating risk and possibly enhancing pillar strengths. Although financial conditions remain pressured, staying attuned to regulatory changes might unlock valuable strategic opportunities for the company.
- IR / PR agency
- JTC Team
- IR email
- info@cyclotherapeutics.com
- IR page
- Investor relations
- Headquarters
- 1180 Alachua, FL 32616-1180
- CEO
- Howard S. Jonas
- CFO
- David Polinsky
- SEC CIK
- 0000922247
- Website
- Company website
- Market cap
- $23.6M
- Enterprise value
- $34.9M
- Price to book
- 59.10
- Price to sales
- 27.09
- EV / EBITDA
- -0.47
- Revenue (TTM)
- $871K
- Gross profit (TTM)
- $794K
- EBITDA
- $-24.7M
- Operating margin
- -3545.9%
- Profit margin
- 0.0%
- Rev growth YoY
- -52.8%
- Return on equity
- -22663.9%
- Return on assets
- -284.3%
- EPS (TTM)
- $-0.90
- Wall St. target price
- $0.95
- Shares outstanding
- 32.7M
- Insider ownership
- 48.5%
- Institutional ownership
- 11.4%
- Beta
- -0.57
- Full-time employees
- 8
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for CYTH (CYTH)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for CYTH (CYTH), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Neutral / Wait. Mixed data profile. Await clearer directional signal. (0 bullish signals, 0 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CYTH are maintained by Cannabis Investor News and refreshed throughout the trading day.